ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

11:00AM-11:15AM: Abstract Number: 0964

Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases

Abstracts: Infection-related Rheumatic Disease (0962–0965)

11:15AM-11:30AM: Abstract Number: 0965

Anti-TNF Usage in Patients with HIV Infection 2003-2021: Long Term Safety and Followup

Abstracts: Infection-related Rheumatic Disease (0962–0965)

11:15AM-11:30AM: Abstract Number: 0959

Impact of Systemic Lupus Disease Activity State on Flare Risk After Hydroxychloroquine Maintenance, Reduction or Discontinuation in a Multinational Inception Cohort

Plenary II (0956–0961)

11:15AM-11:30AM: Abstract Number: 0969

Loss of Balance Between Protective and Pro-inflammatory Synovial Tissue T Cell Polyfunctionality Predates Clinical Onset of Rheumatoid Arthritis

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0966–0969)

11:30AM-11:45AM: Abstract Number: 0960

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes

Plenary II (0956–0961)

11:45AM-12:00PM: Abstract Number: 0961

Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction

Plenary II (0956–0961)

2:00PM-2:15PM: Abstract Number: 0970

Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes

Abstracts: SLE – Etiology & Pathogenesis (0970–0973)

2:00PM-2:15PM: Abstract Number: 0980

Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Bugs & Drugs (0980–0983)

2:00PM-2:15PM: Abstract Number: 0974

Use of Disease-Modifying Anti-Rheumatic Drug Associated with Lower Incidence of Anti-Tumor Necrosis Factor Induced Psoriasis in Children with Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis

Abstracts: Pediatric Rheumatology – Clinical (0974–0979)

2:15PM-2:30PM: Abstract Number: 0981

Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Bugs & Drugs (0980–0983)

2:15PM-2:30PM: Abstract Number: 0975

Data-driven MRI Definitions for Active and Structural Sacroiliac Joint Lesions in Juvenile Spondyloarthritis Typical of Axial Disease

Abstracts: Pediatric Rheumatology – Clinical (0974–0979)

2:15PM-2:30PM: Abstract Number: 0971

Longitudinal CyTOF Immunophenotyping Reveals Distinct Patterns of T cell-B Cell Dysregulation in SLE

Abstracts: SLE – Etiology & Pathogenesis (0970–0973)

2:30PM-2:45PM: Abstract Number: 0982

B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Bugs & Drugs (0980–0983)

2:30PM-2:45PM: Abstract Number: 0976

Cumulative Social Disadvantage Predicts an Arthritis Diagnosis: A Cross-sectional Analysis of the National Survey of Children’s Health (NSCH)

Abstracts: Pediatric Rheumatology – Clinical (0974–0979)

2:30PM-2:45PM: Abstract Number: 0972

Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells Which Enhances TGF-β1 Activation and Promotes Tissue Fibrosis in Lupus Nephritis

Abstracts: SLE – Etiology & Pathogenesis (0970–0973)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].